HCV Inhibitor

Uprifosbuvir is an antiviral agent. Uprifosbuvir is a NS5b inhibitor developed for the research of chronic hepatitis C virus.

Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection.

Ruzasvir (MK-8408) is an orally active inhibitor for genotypic HCV nonstructural protein 5A (NS5A), which inhibits the replication of NS5A mutants GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a and GT4a with EC₉₀ ranging from 0.003 to 0.067 nM. Ruzasvir exhibits good pharmacokinetic characters in rhesus monkey model.

Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination.

KIN101 is a potent RNA viral inhibitor with IC₅₀s of 2 μM, >5 μM for influenza virus and Dengue virus (DNV), respectively. KIN101, an isoflavone agonist of IRF-3 dependent signaling, induces IRF-3 nuclear translocation. KIN101 has broad-spectrum activity against RNA viruses.

RIG-1 modulator 1 (Compound of claim 13) is an anti-viral compound which can be used against viral infections including influenza virus, HBV, HCV and HIV.

Ribavirin (Standard) is the analytical standard of Ribavirin. This product is intended for research and analytical applications. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC₅₀s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC₅₀s of 200 nM and 150 nM, respectively.

Yimitasvir diphosphate (Emitasvir diphosphate; DAG-181 diphosphate) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir diphosphate is applicable to research related to HCV infection.

HCV-IN-29 is a hepatitis C virus (HCV) inhibitor exacted from patent US8329159B2, compound 1e.

Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a K_d of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC₅₀ of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis.

Cajaninstilbene acid is a potent HCV inhibitor with an IC₅₀ of 3.17 μM. Cajaninstilbene acid inhibits HCV replications via down-regulates a cellular protein chondroitin sulfate N-acetylgalactosaminyltransferase 1.

Sofosbuvir (Standard) is the analytical standard of Sofosbuvir. This product is intended for research and analytical applications. Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC₅₀ of 92 nM.

Daclatasvir (dihydrochloride) (Standard) is the analytical standard of Daclatasvir (dihydrochloride). This product is intended for research and analytical applications. Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 µM and 3.27 µM, respectively.

ML283 is a HCV NS3 helicase inhibitor (IC₅₀: 2.6 μM). ML283 also inhibits DenV ATPase (IC₅₀: 4.0 μM).

Mizoribine (Standard) is the analytical standard of Mizoribine. This product is intended for research and analytical applications. Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant. Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC₅₀s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively.

Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.

NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form. NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA.

ABT-072 is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM).

GS-6620 is potent and selective HCV inhibitor. GS-6620 inhibits HCV replication in genotype 1-6 subgenomic replicons and genotype 2a infectious virus, with EC₅₀ values of 0.048-0.68 μM. GS-6620 can be used for the researches of infection and inflammation, such as Hepatitis C Virus (HCV).